# Research timeline and gaps: Retatrutide: Clinical Weight Loss and Supply Claims

Selected publication milestones, not an exhaustive history or discovery priority claim.

**2013 — Dual-incretin translational experiments establish alternative receptor architectures before retatrutide.** [Original PMID24174327](https://pubmed.ncbi.nlm.nih.gov/24174327/).

**2013 — Glucagon/FGF21genetic perturbation separates some weight/energy effects from glucose effects.** [Original PMID23305646](https://pubmed.ncbi.nlm.nih.gov/23305646/).

**2022 — LY3437943discovery combines receptor/mouse perturbation and early humanexposure/weight observations.** [Original PMID35985340](https://pubmed.ncbi.nlm.nih.gov/35985340/).

**2023 — Randomized phase2obesityweight efficacy demonstrated through48weeks.** [Original PMID37366315](https://pubmed.ncbi.nlm.nih.gov/37366315/).

**2023 — Randomized phase2T2Dtrial addsdulagutide active comparison and dose boundaries.** [Original PMID37385280](https://pubmed.ncbi.nlm.nih.gov/37385280/).

**2025 — Directtirzepatide-versus-semaglutide comparison demonstrates why head-to-headandcross-trialclaims differ.** [Original PMID40353578](https://pubmed.ncbi.nlm.nih.gov/40353578/).

**2025 — RetatrutideDXAbodycomposition substudypublished with missingness limits.** [Original PMID40609566](https://pubmed.ncbi.nlm.nih.gov/40609566/).

**2026 — 40-week retatrutide diabetesphase3report published with weight a secondaryendpoint.** [Original PMID42250575](https://pubmed.ncbi.nlm.nih.gov/42250575/).

**2026 — 29September2026TRIUMPH1reports80-week obesityweight and clinicalsubgroupoutcomes.** [Original PMID42814954](https://pubmed.ncbi.nlm.nih.gov/42814954/).

**2026 — 29September2026TRIUMPH2reports80-week weight efficacy inobesitywithT2D.** [Original PMID42810372](https://pubmed.ncbi.nlm.nih.gov/42810372/).

## Research gaps

Direct matched retatrutide versus modern obesity-dose semaglutide/tirzepatide superiority with comparable estimands and durability.

Retatrutide-specific withdrawal/rechallenge and long-term weight/function maintenance rather than class extrapolation.

Human contribution of each receptor at measured therapeutic exposure, including energy expenditure and intake partition.

Hard cardiovascular/renal outcomes and longer safety follow-up; surrogate lipid and inflammation analyses are insufficient.

Muscle strength/function and clinically important composition outcomes, withDXAmissingness disclosed.

Independent identified retatrutide supply-batch quality and product-linked clinical evidence; no assay result from semaglutide characterizes everyretatrutide vial.

## Boundary experiment

A blinded randomized retatrutide versus contemporary obesity-dose dual/GLP1 comparator trial, matched eligibility, lifestyle support and treatment-regimen estimand over72weeks, with a prespecified retatrutide continuation-versus-withdrawal phase in baseline-defined tolerators and independent weight/function assessment. Add human energy-expenditure/intake/body-composition substudy without interpreting correlations as receptor necessity.